UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

IN4 Local therapy considerations in BRCA1/2 mutations carriers with breast cancer

Breast (Edinburgh), 2014-11, Vol.23, p.S2-S3

Evron, E

2014

Volltextzugriff (PDF)

Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer

Annals of oncology, 2019-03, Vol.30 (3), p.412-417

2019

Volltextzugriff (PDF)

Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR

The Lancet (British edition), 2001-04, Vol.357 (9265), p.1335-1336

2001

Volltextzugriff (PDF)

Chemotherapy may eradicate ductal carcinoma in situ (DCIS) but not the associated microcalcifications

European journal of surgical oncology, 2017-08, Vol.43 (8), p.1415-1420

2017

Volltextzugriff (PDF)

P169 Clinical outcomes in patients (pts) with estrogen receptor (ER)+ stage I breast cancer (BC) and Recurrence Score (RS) 26–30: Real-world data

Breast (Edinburgh), 2023-04, Vol.68, p.S81-S82

2023

Volltextzugriff (PDF)

1963 First prospective outcome data in 930 patients with more than 5 year median follow up in whom treatment decisions in clinical practice have been made incorporating the 21-Gene Recurrence Score

European journal of cancer (1990), 2015-09, Vol.51, p.S321-S321

2015

Volltextzugriff (PDF)

1040 Propionibacterium acnes carbohydrates from acne associated phylotypes induce distinct inflammatory response in comparison to carbohydrates from healthy phylotypes: A potential ligand implicated in acne disease pathogenesis

Journal of investigative dermatology, 2018-05, Vol.138 (5), p.S176-S176

2018

Volltextzugriff (PDF)

452 Cutibacterium acnes carbohydrates from multiple phylotypes induce IL-17: A potential ligand implicated in acne disease pathogenesis

Journal of investigative dermatology, 2019-05, Vol.139 (5), p.S78-S78

2019

Volltextzugriff (PDF)

Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast

Oncogene, 2003-04, Vol.22 (13), p.2021-2033

2003

Volltextzugriff (PDF)

149P Clinical outcomes in ER+ breast cancer patients with recurrence score 26-30-guided therapy: Real-world data

Annals of oncology, 2022-09, Vol.33, p.S607-S608

2022

Volltextzugriff (PDF)

Hypermethylation of 14-3-3 σ (stratifin) is an early event in breast cancer

Oncogene, 2001-06, Vol.20 (26), p.3348-3353

2001

Volltextzugriff (PDF)

DNA methylation of RASSF1A, HIN‐1, RAR‐β, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma

International journal of cancer, 2003-12, Vol.107 (6), p.970-975

2003

Volltextzugriff (PDF)

333PRibociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

333P - Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

Annals of oncology, 2019-10, Vol.30, p.v118-v118

2019

Volltextzugriff (PDF)

Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

Annals of oncology, 2019-10, Vol.30, p.v118

2019

Volltextzugriff (PDF)

Compromised HOXA5 function can limit p53 expression in human breast tumours

Nature (London), 2000-06, Vol.405 (6789), p.974-978

2000

Volltextzugriff (PDF)

High Frequency of Hypermethylation at the 14-3-3 σ Locus Leads to Gene Silencing in Breast Cancer

Proceedings of the National Academy of Sciences - PNAS, 2000-05, Vol.97 (11), p.6049-6054

2000

Volltextzugriff (PDF)

Abstract P4-21-17: BELIS: Safety and tolerability of at home administration of trastuzumab (Herceptin®) subcutaneous for the treatment of patients with HER2-positive early breast cancer

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P4-P4-21-17

2017

Volltextzugriff (PDF)

Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation

Cancer research (Chicago, Ill.), 2001-03, Vol.61 (6), p.2782-2787

2001

Volltextzugriff (PDF)

Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation

Cancer research (Chicago, Ill.), 2001-02, Vol.61 (3), p.921-925

2001

Volltextzugriff (PDF)

Breast cancer in octogenarians

Cancer, 2006-04, Vol.106 (8), p.1664-1668

2006

Volltextzugriff (PDF)

Abstract P5-20-06: RAD001 (Everolimus) in combination with Letrozole in the treatment of postmenopausal women with estrogen receptor positive Metastatic Breast cancer after failure of hormonal therapy – a phase II study

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.P5-P5-20-06

2012

Volltextzugriff (PDF)

Abstract P5-08-02: Real-life analysis evaluating 1594 N0/Nmic breast cancer patients for whom treatment decisions incorporated the 21-gene recurrence score result: 5-year KM estimate for breast cancer specific survival with recurrence score results ≤30 is >98

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P5-P5-08-02

2016

Volltextzugriff (PDF)

Abstract P2-14-04: Co-Administration of GnRH-Agonists with Adjuvant Chemotherapy in Young Breast Cancer Patients: The Effect on Ovarian Function and on Clinical Outcome

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.P2-P2-14-04

2010

Volltextzugriff (PDF)

Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers

Oncogene, 1998-06, Vol.16 (24), p.3215-3218

1998

Volltextzugriff (PDF)

1 – 25 von 121

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(100)
Mit Volltextzugriff
(98)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

IN4 Local therapy considerations in BRCA1/2 mutations carriers with breast cancer

Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer

Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR

Chemotherapy may eradicate ductal carcinoma in situ (DCIS) but not the associated microcalcifications

P169 Clinical outcomes in patients (pts) with estrogen receptor (ER)+ stage I breast cancer (BC) and Recurrence Score (RS) 26–30: Real-world data

1963 First prospective outcome data in 930 patients with more than 5 year median follow up in whom treatment decisions in clinical practice have been made incorporating the 21-Gene Recurrence Score

1040 Propionibacterium acnes carbohydrates from acne associated phylotypes induce distinct inflammatory response in comparison to carbohydrates from healthy phylotypes: A potential ligand implicated in acne disease pathogenesis

452 Cutibacterium acnes carbohydrates from multiple phylotypes induce IL-17: A potential ligand implicated in acne disease pathogenesis

Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast

149P Clinical outcomes in ER+ breast cancer patients with recurrence score 26-30-guided therapy: Real-world data

Hypermethylation of 14-3-3 σ (stratifin) is an early event in breast cancer

DNA methylation of RASSF1A, HIN‐1, RAR‐β, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma

333PRibociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

333P - Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

Compromised HOXA5 function can limit p53 expression in human breast tumours

High Frequency of Hypermethylation at the 14-3-3 σ Locus Leads to Gene Silencing in Breast Cancer

Abstract P4-21-17: BELIS: Safety and tolerability of at home administration of trastuzumab (Herceptin®) subcutaneous for the treatment of patients with HER2-positive early breast cancer

Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation

Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation

Breast cancer in octogenarians

Abstract P5-20-06: RAD001 (Everolimus) in combination with Letrozole in the treatment of postmenopausal women with estrogen receptor positive Metastatic Breast cancer after failure of hormonal therapy – a phase II study

Abstract P5-08-02: Real-life analysis evaluating 1594 N0/Nmic breast cancer patients for whom treatment decisions incorporated the 21-gene recurrence score result: 5-year KM estimate for breast cancer specific survival with recurrence score results ≤30 is >98

Abstract P2-14-04: Co-Administration of GnRH-Agonists with Adjuvant Chemotherapy in Young Breast Cancer Patients: The Effect on Ovarian Function and on Clinical Outcome

Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers

Suchergebnisse filtern